Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates.

Basic & clinical pharmacology & toxicology - 1 May 2004

Takahata Takenori, Yasui-Furukori Norio, Yoshiya Gen, Uno Tsukasa, Sugawara Kazunobu, Tateishi Tomonori

Abstract excerpt

An in vitro study has recently suggested that a proton pump inhibitor, omeprazole, is a modest substrate of P-glycoprotein. Several studies have shown P-glycoprotein is involved in the absorption and excretion of fexofenadine. Therefore, we examined the effect of fexofenadine on the pharmacokinetics of omeprazole. Eight healthy volunteers participated in this study. They received a single oral dose of 40 mg...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Ulcer Agents
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Drug Interactions

Share to Fluorescent Dyes

Share to Mixed Function Oxygenases

Share to Omeprazole

Share to Rhodamine 123

Source

Identifiers

PMID: 15125696
DOI: 10.1111/j.1742-7843.2004.pto940509.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates.PMID 15125696Read ↗

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.Semantic proximity Read ↗

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women.Semantic proximity Read ↗

Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies.Semantic proximity Read ↗

Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers.Semantic proximity Read ↗

Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9.Semantic proximity Read ↗

Faster clearance of omeprazole in mutant Nagase analbuminemic rats: possible roles of increased protein expression of hepatic CYP1A2 and lower plasma protein binding.Semantic proximity Read ↗

No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.Semantic proximity Read ↗

Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate.Semantic proximity Read ↗

Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.Semantic proximity Read ↗

Time-dependent interaction between lopinavir/ritonavir and fexofenadine.Semantic proximity Read ↗

Effect of Omeprazole and Dextromethorphan on the Urinary Metabolic Ratio of Flurbiprofen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.